Hemolytic adverse events with immune globulin products: product factors and patient risks

Publisher： John Wiley & Sons Inc

E-ISSN： 1537-2995|55|S2|S2-S5

ISSN： 0041-1132

Source： TRANSFUSION, Vol.55, Iss.S2, 2015-07, pp. : S2-S5

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Hemolytic events after the administration of lyophilized versus liquid immune globulin: an analysis of a single manufacturer's safety database

By  

TRANSFUSION, Vol. 55, Iss. 8, 2015-08 ,pp. : 1847-1854

John Wiley & Sons Inc

Access to resources Recommend Favorite

Occurrence of hemolytic reactions on the same day as immune globulin product administrations during 2008 to 2014

By  

TRANSFUSION, Vol. 58, Iss. 1, 2018-01 ,pp. : 70-80

John Wiley & Sons Inc

Access to resources Recommend Favorite

Hemolytic events associated with intravenous immune globulin therapy: a qualitative analysis of 263 cases reported to four manufacturers between 2003 and 2012

By  

TRANSFUSION, Vol. 55, Iss. S2, 2015-07 ,pp. : S36-S46

John Wiley & Sons Inc

Access to resources Recommend Favorite

Do immune complexes play a role in hemolytic sequelae of intravenous immune globulin?

By  

TRANSFUSION, Vol. 55, Iss. S2, 2015-07 ,pp. : S86-S89

John Wiley & Sons Inc

Access to resources Recommend Favorite

Patient‐specific risk factors of adverse drug events in adult inpatients – evidence detected using the Global Trigger Tool method

By  

JOURNAL OF CLINICAL NURSING, Vol. 24, Iss. 3-4, 2015-02 ,pp. : 582-591

John Wiley & Sons Inc

Access to resources Recommend Favorite